PUBLIC COMPANYA biotechnology company that develops and sells medicines for serious illnesses.
Amgen makes biologic therapies for conditions such as cancer, heart disease and bone disorders. It sells mainly to wholesalers, pharmacies and healthcare providers. The stock is listed on the Nasdaq, and its annual report gives a full description of the business, its risks and its audited financial statements. The filings describe competition from biosimilar products and patent expirations, which are important parts to read.
Amgen is a biotechnology company based in Thousand Oaks, California. It develops medicines for conditions such as high cholesterol, bone loss, arthritis and cancer, using large molecule drugs made in living cells.
It earns from selling prescription drugs, most of which are protected by patents for a set period. After a patent ends, cheaper copies can enter the market, so a company like this must keep creating or buying new medicines.
Drug trials can fail, rules on pricing can change, and patent expirations are a regular challenge. Biotech stocks can move sharply on trial news. Reading the drug pipeline, the list of medicines in testing, tells you where future growth must come from.
What is a biosimilar?
A close, lower cost copy of a biologic drug after its patent ends.
Why do trials matter?
A drug must prove it works and is safe before it can be sold.
What is a pipeline?
The group of drugs a company is developing.
Open the latest annual report, called a 10-K, and look at the top selling products, patent dates and the drug pipeline. Reading the company in its own words is the best way to see how it really works.
This page is for education only. It is not advice to buy or sell anything.
Official reports for Amgen Inc. are on the SEC site. Open the filings for AMGN. Public company facts here come from official filings and the company itself.
Claim this profile to correct facts, add your website and news, and keep it current. Basic claiming is free. Paid features, like press releases and spotlights, are always labeled.
Claim this profile See company spotlightsProfile written by Positive Stocks from public information, last checked in October 2026. Details change, so confirm with the company and its filings. This is for education only. It is not a recommendation to buy or sell anything. Investing involves risk, including loss of money.